Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ayala Pharmaceuticals, Inc.ADXS · Entity 93434 | Director | May 04, 2020 | May 05, 2020 |
| BIOVIE INC.BIVI · Entity 7702 | Director | November 20, 2024 | January 07, 2025 |
| COMSovereign Holding Corp.COMS · Entity 114048 | Director | April 01, 2021 | April 06, 2021 |
| Celularity IncCELU · Entity 7145 | Director | December 19, 2024 | January 06, 2025 |
| Context Therapeutics Inc.CNTX · Entity 7406 | Director | June 13, 2024 | June 14, 2024 |
| Cryoport, Inc.CYRX · Entity 5125 | Director | May 17, 2024 | May 21, 2024 |
| Cuentas Inc.CUEN · Entity 8361 | Director | September 13, 2018 | December 21, 2018 |
| Frontier Investment CorpFICV · Entity 111626 | Director | June 30, 2021 | July 12, 2021 |
| LISATA THERAPEUTICS, INC.CLBS · Entity 7814 | Director | January 09, 2017 | January 31, 2017 |
| MetaStat, Inc.MTST.OB · Entity 170270 | Director | April 04, 2017 | April 06, 2017 |
| Ontrak, Inc.OTRK · Entity 78207 | Director | February 11, 2021 | February 16, 2021 |
| Sidus Space Inc.SIDU · Entity 6254 | Director | January 18, 2024 | January 24, 2024 |
| Titan Environmental Solutions Inc.TRIQ · Entity 80360 | Director | April 05, 2021 | April 06, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ayala Pharmaceuticals, Inc.
Report date May 04, 2020 · Filed May 05, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.66 · Expires 2030-05-04 | Direct | 13,000 |
Reported balance
After 2020-05-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-05-04 · Grant · Acquired 13,000 · Balance 13,000 F1: This award relates to an incentive grant awarded by the Compensation Committee and is subject to the terms of our 2015 Incentive Plan. The award vests one-third on May 4, 2021, one-third on May 4, 2022, and will be fully vested on May 4, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: This award relates to an incentive grant awarded by the Compensation Committee and is subject to the terms of our 2015 Incentive Plan. The award vests one-third on May 4, 2021, one-third on May 4, 2022, and will be fully vested on May 4, 2023.
BIOVIE INC.
Report date November 20, 2024 · Filed January 07, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 40,643 |
Reported balance
After 2024-11-20 transaction · row 1
1 source rowRow 1 · 2024-11-20 · Grant · Acquired 34,200 · Balance 40,643 F1: Represents a restricted stock unit ("RSU") grant, which was approved by the compensation committee of the issuer's board of directors, subject to board approval, which was obtained on November 20, 2024. Each RSU represents a contingent right to receive one share of the issuer's Class A common stock. The RSUs vest in four equal installments on February 8, 2025, May 8, 2025, August 8, 2025 and the earlier of November 8, 2025 and the date of the issuer's 2025 annual shareholders' meeting. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.90 · Expires 2029-12-20 | Direct | 23,155 |
Reported balance
After 2024-12-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-12-20 · Grant · Acquired 23,155 · Balance 23,155 F2: The options vest in three equal installments on December 20, 2024, December 20, 2025 and December 20, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted stock unit ("RSU") grant, which was approved by the compensation committee of the issuer's board of directors, subject to board approval, which was obtained on November 20, 2024. Each RSU represents a contingent right to receive one share of the issuer's Class A common stock. The RSUs vest in four equal installments on February 8, 2025, May 8, 2025, August 8, 2025 and the earlier of November 8, 2025 and the date of the issuer's 2025 annual shareholders' meeting.
F2: The options vest in three equal installments on December 20, 2024, December 20, 2025 and December 20, 2026.
COMSovereign Holding Corp.
Report date April 01, 2021 · Filed April 06, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.75 · Expires 2026-04-01 | Direct | 225,000 |
Reported balance
After 2021-04-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-04-01 · Grant · Acquired 225,000 · Balance 225,000 F1: Consists of Stock Option awards made pursuant to the COMS 2020 Long-Term Incentive Plan. F2: The Stock Option awards vest over a two-year period, at a rate of one-half on each anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of Stock Option awards made pursuant to the COMS 2020 Long-Term Incentive Plan.
F2: The Stock Option awards vest over a two-year period, at a rate of one-half on each anniversary of the grant date.
Celularity Inc
Report date December 19, 2024 · Filed January 06, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 67,416 |
Reported balance
After 2024-12-19 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-12-19 · Grant · Acquired 67,416 · Balance 67,416 F1: These shares represent restricted stock units ("RSUs") granted under the Celularity Inc. 2021 Equity Incentive Plan (the "2021 Plan"), with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant, December 19, 2024, and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date. F2: Includes 67,416 RSUs granted under the 2021 Plan, with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant, December 19, 2024, and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.23 · Expires 2034-12-19 | Direct | 202,857 |
Reported balance
After 2024-12-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-12-19 · Grant · Acquired 84,746 · Balance 202,857 F3: This option was granted under the 2021 Plan and shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant, December 19, 2024, and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares represent restricted stock units ("RSUs") granted under the Celularity Inc. 2021 Equity Incentive Plan (the "2021 Plan"), with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant, December 19, 2024, and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date.
F2: Includes 67,416 RSUs granted under the 2021 Plan, with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant, December 19, 2024, and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date.
F3: This option was granted under the 2021 Plan and shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant, December 19, 2024, and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date.
Context Therapeutics Inc.
Report date June 13, 2024 · Filed June 14, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.97 · Expires 2034-06-12 | Direct | 50,000 |
Reported balance
After 2024-06-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-13 · Grant · Acquired 50,000 · Balance 50,000 F1: The option vests and becomes exercisable on the earlier of (i) June 13, 2025 (the one-year anniversary of the date of grant) or (ii) the Issuer's 2025 annual meeting of stockholders, subject to continued service with the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and becomes exercisable on the earlier of (i) June 13, 2025 (the one-year anniversary of the date of grant) or (ii) the Issuer's 2025 annual meeting of stockholders, subject to continued service with the Issuer.
Cryoport, Inc.
Report date May 17, 2024 · Filed May 21, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 112,845 |
Reported balance
After 2024-05-17 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-05-17 · Grant · Acquired 12,845 · Balance 112,845 F1: Reflects grant of restricted stock rights that vest in full on May 17, 2025, and upon vesting automatically convert to shares of common stock on a one-for-one basis. |
| Option (Right to Buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $12.65 · Expires 2031-05-17 | Direct | 23,830 |
Reported balance
After 2024-05-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-05-17 · Grant · Acquired 23,830 · Balance 23,830 F2: 1/12th of the options vest on the 17th of the month for twelve months beginning June 17, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects grant of restricted stock rights that vest in full on May 17, 2025, and upon vesting automatically convert to shares of common stock on a one-for-one basis.
F2: 1/12th of the options vest on the 17th of the month for twelve months beginning June 17, 2024.
Cuentas Inc.
Report date September 13, 2018 · Filed December 21, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to purchase Common Stock*SEC Table II · derivative / convertible security · Conversion / exercise price $3.00 · Expires 2023-09-13 | Direct | 30,000 |
Reported balance
After 2018-09-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-09-13 · Grant · Acquired 30,000 · Balance 30,000 F1: The 30,000 options to purchase shares of the Issuer's common stock were issued in connection with a grant under the Issuer's 2018 Equity Stock Incentive Plan. F2: 10,000 options are exercisable at 9/13/2018; 10,000 options are exercisable at 9/13/2019; 10,000 options are exercisable at 9/13/2020. |
Filing footnotes · ownership attribution and instrument terms
F1: The 30,000 options to purchase shares of the Issuer's common stock were issued in connection with a grant under the Issuer's 2018 Equity Stock Incentive Plan.
F2: 10,000 options are exercisable at 9/13/2018; 10,000 options are exercisable at 9/13/2019; 10,000 options are exercisable at 9/13/2020.
Frontier Investment Corp
Report date June 30, 2021 · Filed July 12, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary Shares, $0.0001 par valueSEC Table I · non-derivative | IndirectIndirect economic interest for the value of the identified amount of shares. | 31,250 |
Reported balance
Holding disclosure · report date 2021-06-30 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 31,250 |
LISATA THERAPEUTICS, INC.
Report date January 09, 2017 · Filed January 31, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,177 |
Reported balance
After 2017-01-09 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2017-01-09 · Grant · Acquired 1,650 · Balance 7,177 F1: Represents 1,650 shares of restricted stock granted under the Issuer's 2015 Equity Compensation Plan that will vest on January 9, 2018. F2: Includes 2,775 shares of unvested restricted stock granted under the Issuer's compensation plans. |
| Options to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $3.54 · Expires 2027-01-09 | Direct | 2,750 |
Reported balance
After 2017-01-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-01-09 · Grant · Acquired 2,750 · Balance 2,750 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents 1,650 shares of restricted stock granted under the Issuer's 2015 Equity Compensation Plan that will vest on January 9, 2018.
F2: Includes 2,775 shares of unvested restricted stock granted under the Issuer's compensation plans.
MetaStat, Inc.
Report date April 04, 2017 · Filed April 06, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 52,696 |
Reported balance
After 2017-04-04 transaction · row 1
1 source rowRow 1 · 2017-04-04 · Purchase · Acquired 20,000 · Balance 52,696 F1: Reflects the issuance of 20,000 restricted shares of fully vested common stock approved by the board of directors on April 4, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the issuance of 20,000 restricted shares of fully vested common stock approved by the board of directors on April 4, 2017.
Ontrak, Inc.
Report date February 11, 2021 · Filed February 16, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $86.57 · Expires 2026-02-11 | Direct | 4,882 |
Reported balance
After 2021-02-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-02-11 · Grant · Acquired 4,882 · Balance 4,882 F1: These securities were granted to Mr. Berman for his services as a member of the Company's Board of Directors and Chairman of the Audit Committee. F2: 1,220 shares shall vest at the end of each quarter beginning January 1, 2021, such that all shares pursuant to the option shall be vested on December 31, 2021. Quarterly vesting of the options will be subject to Mr. Berman attending board meetings, unless such absence is excused by the Chairman of the Board. |
Filing footnotes · ownership attribution and instrument terms
F1: These securities were granted to Mr. Berman for his services as a member of the Company's Board of Directors and Chairman of the Audit Committee.
F2: 1,220 shares shall vest at the end of each quarter beginning January 1, 2021, such that all shares pursuant to the option shall be vested on December 31, 2021. Quarterly vesting of the options will be subject to Mr. Berman attending board meetings, unless such absence is excused by the Chairman of the Board.
Sidus Space Inc.
Report date January 18, 2024 · Filed January 24, 2024
This filing explicitly reported no securities owned.
Titan Environmental Solutions Inc.
Report date April 05, 2021 · Filed April 06, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | Direct | 350,000 |
Reported balance
After 2021-04-05 transaction · row 1
1 source rowRow 1 · 2021-04-05 · Grant · Acquired 250,000 · Balance 350,000 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 25, 2021 Filed Mar 1, 2021 20:00 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionOptions to purchase common stock · Derivative | 16,115 | $0.00 Strike: $4.80 | $0.00 |
DisclosureSEC source: 0001104659-21-030250 · tm218187d1_4seq1.xml · derivative · entry 4 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,885 Underlying: Common Stock · 16,115 shares Expires 2027-06-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/12 of the 35,000 options originally granted vested on the 23rd of the month for twelve months beginning on July 23, 2017. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 20:00 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionOptions to purchase common stock · Derivative | 4,967 | $0.00 Strike: $4.56 | $0.00 |
DisclosureSEC source: 0001104659-21-030250 · tm218187d1_4seq1.xml · derivative · entry 3 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,967 shares Expires 2025-01-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/12 of the 16,667 options originally granted vested on the 12th of the month for twelve months beginning on February 12, 2015. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 20:00 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionCommon Stock | 16,115 | $4.80 | $77,352.00 |
DisclosureSEC source: 0001104659-21-030250 · tm218187d1_4seq1.xml · nonDerivative · entry 2 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,082 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 20:00 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionCommon Stock | 4,967 | $4.56 | $22,649.52 |
DisclosureSEC source: 0001104659-21-030250 · tm218187d1_4seq1.xml · nonDerivative · entry 1 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,967 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 19:22 UTC | Ontrak, Inc. OTRK · Entity 78207 | GrantOption (right to buy) · Derivative | 4,882 | $0.00 Strike: $86.57 | $0.00 |
DisclosureSEC source: 0001593968-21-000497 · primary_01.xml · derivative · entry 1 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,882 Underlying: Ontrak, Inc. Common Stock · 4,882 shares Expires 2026-02-11 F1 · kind: These securities were granted to Mr. Berman for his services as a member of the Company's Board of Directors and Chairman of the Audit Committee. F2 · derivative.exercise_date: 1,220 shares shall vest at the end of each quarter beginning January 1, 2021, such that all shares pursuant to the option shall be vested on December 31, 2021. Quarterly vesting of the options will be subject to Mr. Berman attending board meetings, unless such absence is excused by the Chairman of the Board. Read SEC document |
| December 18, 2020 Filed Sep 29, 2021 10:56 UTC | BIOVIE INC. BIVI · Entity 7702 | GrantStock Option (right to buy) · Derivative | 102,500 | $0.00 Strike: $13.91 | $0.00 |
DisclosureSEC source: 0001520138-21-000592 · ownership.xml · derivative · entry 3 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,500 Underlying: Common Stock · 102,500 shares Expires 2025-12-18 F1 · derivative.exercise_date: This option was 25% vested upon grant, with an additional 25% on each of the first three anniversaries of the grant. Read SEC document |
| November 11, 2020 Filed Nov 13, 2020 10:22 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionOptions to purchase common stock · Derivative | 11,700 | $0.00 Strike: $4.56 | $0.00 |
DisclosureSEC source: 0001104659-20-124763 · tm2035915d1_4.xml · derivative · entry 5 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,967 Underlying: Common Stock · 11,700 shares Expires 2025-01-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/48 of the 16,667 options originally granted vested on the 12th of the month for forty-eight months beginning on January 12, 2015. Read SEC document |
| November 11, 2020 Filed Nov 13, 2020 10:22 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionOptions to purchase common stock · Derivative | 8,300 | $0.00 Strike: $3.07 | $0.00 |
DisclosureSEC source: 0001104659-20-124763 · tm2035915d1_4.xml · derivative · entry 4 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,300 shares Expires 2025-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/48 of the 113,300 options originally granted vested on the 19th of each month for forty-eight months beginning on August 19, 2015. Read SEC document |
| November 11, 2020 Filed Nov 13, 2020 10:22 UTC | Cryoport, Inc. CYRX · Entity 5125 | SaleCommon Stock | 20,000 | $55.55 | $1,110,934.00 |
DisclosureSEC source: 0001104659-20-124763 · tm2035915d1_4.xml · nonDerivative · entry 3 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| November 11, 2020 Filed Nov 13, 2020 10:22 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionCommon Stock | 11,700 | $4.56 | $53,352.00 |
DisclosureSEC source: 0001104659-20-124763 · tm2035915d1_4.xml · nonDerivative · entry 2 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 11, 2020 Filed Nov 13, 2020 10:22 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionCommon Stock | 8,300 | $3.07 | $25,481.00 |
DisclosureSEC source: 0001104659-20-124763 · tm2035915d1_4.xml · nonDerivative · entry 1 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,300 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 29, 2020 Filed Jul 31, 2020 17:18 UTC | Cryoport, Inc. CYRX · Entity 5125 | OtherWarrants to purchase common stock · Derivative | 8,138 | $0.00 Strike: $3.57 | $0.00 |
DisclosureSEC source: 0001104659-20-089166 · tm2026274d1_4.xml · derivative · entry 2 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 0 Underlying: Common Stock · 8,138 shares Expires 2020-07-29 Read SEC document |
| July 29, 2020 Filed Jul 31, 2020 17:18 UTC | Cryoport, Inc. CYRX · Entity 5125 | OtherCommon Stock | 8,138 | $3.57 | $29,052.66 |
DisclosureSEC source: 0001104659-20-089166 · tm2026274d1_4.xml · nonDerivative · entry 1 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 9,250 Read SEC document |
| May 28, 2020 Filed Jun 2, 2020 20:26 UTC | Cryoport, Inc. CYRX · Entity 5125 | OtherWarrants to purchase common stock · Derivative | 1,112 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001104659-20-069110 · tm2021676d1_4.xml · derivative · entry 2 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 0 Underlying: Common Stock · 1,112 shares Expires 2020-05-31 Read SEC document |
| May 28, 2020 Filed Jun 2, 2020 20:26 UTC | Cryoport, Inc. CYRX · Entity 5125 | OtherCommon Stock | 1,112 | $6.00 | $6,672.00 |
DisclosureSEC source: 0001104659-20-069110 · tm2021676d1_4.xml · nonDerivative · entry 1 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 1,112 Read SEC document |
| May 04, 2020 Filed May 5, 2020 16:00 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | GrantOption · Derivative | 13,000 | $0.00 Strike: $0.66 | $0.00 |
DisclosureSEC source: 0001493152-20-007725 · ownership.xml · derivative · entry 1 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires 2030-05-04 F1 · derivative.exercise_date: This award relates to an incentive grant awarded by the Compensation Committee and is subject to the terms of our 2015 Incentive Plan. The award vests one-third on May 4, 2021, one-third on May 4, 2022, and will be fully vested on May 4, 2023. Read SEC document |
| May 01, 2020 Filed May 5, 2020 21:11 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantOptions to purchase common stock · Derivative | 35,000 | $0.00 Strike: $18.02 | $0.00 |
DisclosureSEC source: 0001104659-20-057099 · tm2018763d4_4.xml · derivative · entry 1 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2030-05-01 F1 · derivative.exercise_date: 1/12 of these options vest and become exercisable on the 1st of each month for twelve (12) months beginning on 06/01/2020. Read SEC document |
| January 19, 2020 Filed Sep 29, 2021 10:56 UTC | BIOVIE INC. BIVI · Entity 7702 | GrantStock Option (right to buy) · Derivative | 800 | $0.00 Strike: $2.80 | $0.00 |
DisclosureSEC source: 0001520138-21-000592 · ownership.xml · derivative · entry 2 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 800 Underlying: Common Stock · 800 shares Expires 2025-01-19 Read SEC document |
| January 02, 2020 Filed Sep 29, 2021 10:56 UTC | BIOVIE INC. BIVI · Entity 7702 | GrantCommon Stock | 1,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001520138-21-000592 · ownership.xml · nonDerivative · entry 1 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,600 Read SEC document |
| November 19, 2019 Filed Nov 21, 2019 17:43 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionOptions to purchase common stock · Derivative | 5,000 | $0.00 Strike: $3.07 | $0.00 |
DisclosureSEC source: 0001104659-19-066316 · tm1923539d1_form4.xml · derivative · entry 3 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,300 Underlying: Common Stock · 5,000 shares Expires 2025-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/48 of the 113,300 options originally granted vest on the 19th of each month for forty-eight months beginning on August 19, 2015. Read SEC document |
| November 19, 2019 Filed Nov 21, 2019 17:43 UTC | Cryoport, Inc. CYRX · Entity 5125 | SaleCommon Stock | 5,000 | $15.01 | $75,050.00 |
DisclosureSEC source: 0001104659-19-066316 · tm1923539d1_form4.xml · nonDerivative · entry 2 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| November 19, 2019 Filed Nov 21, 2019 17:43 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionCommon Stock | 5,000 | $3.07 | $15,350.00 |
DisclosureSEC source: 0001104659-19-066316 · tm1923539d1_form4.xml · nonDerivative · entry 1 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2019 Filed Nov 15, 2019 18:00 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionOptions to purchase common stock · Derivative | 5,000 | $0.00 Strike: $3.07 | $0.00 |
DisclosureSEC source: 0001104659-19-064821 · tm1923075-1_4.xml · derivative · entry 7 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,300 Underlying: Common Stock · 5,000 shares Expires 2025-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/48 of the 113,300 options originally granted vest on the 19th of each month for forty-eight months beginning on August 19, 2015. Read SEC document |
| November 15, 2019 Filed Nov 15, 2019 18:00 UTC | Cryoport, Inc. CYRX · Entity 5125 | SaleCommon Stock | 5,000 | $15.33 | $76,647.00 |
DisclosureSEC source: 0001104659-19-064821 · tm1923075-1_4.xml · nonDerivative · entry 5 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| November 15, 2019 Filed Nov 15, 2019 18:00 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionCommon Stock | 5,000 | $3.07 | $15,350.00 |
DisclosureSEC source: 0001104659-19-064821 · tm1923075-1_4.xml · nonDerivative · entry 4 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 13, 2019 Filed Nov 15, 2019 18:00 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionOptions to purchase common stock · Derivative | 5,000 | $0.00 Strike: $3.07 | $0.00 |
DisclosureSEC source: 0001104659-19-064821 · tm1923075-1_4.xml · derivative · entry 6 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,300 Underlying: Common Stock · 5,000 shares Expires 2025-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/48 of the 113,300 options originally granted vest on the 19th of each month for forty-eight months beginning on August 19, 2015. Read SEC document |
| November 13, 2019 Filed Nov 15, 2019 18:00 UTC | Cryoport, Inc. CYRX · Entity 5125 | SaleCommon Stock | 98 | $14.98 | $1,468.04 |
DisclosureSEC source: 0001104659-19-064821 · tm1923075-1_4.xml · nonDerivative · entry 3 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| November 13, 2019 Filed Nov 15, 2019 18:00 UTC | Cryoport, Inc. CYRX · Entity 5125 | SaleCommon Stock | 4,902 | $14.99 | $73,502.06 |
DisclosureSEC source: 0001104659-19-064821 · tm1923075-1_4.xml · nonDerivative · entry 2 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98 Read SEC document |
| November 13, 2019 Filed Nov 15, 2019 18:00 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionCommon Stock | 5,000 | $3.07 | $15,350.00 |
DisclosureSEC source: 0001104659-19-064821 · tm1923075-1_4.xml · nonDerivative · entry 1 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 24, 2019 Filed Oct 25, 2019 16:31 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | GrantOption · Derivative | 10,000 | $0.00 Strike: $0.31 | $0.00 |
DisclosureSEC source: 0001493152-19-016010 · ownership.xml · derivative · entry 1 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-10-24 F1 · shares: This award relates to the annual long term incentive grant awarded by the Compensation Committee following the completion of our 2019 Fiscal Year and is subject to the terms of our 2015 Incentive Plan. The award vests one-third on October 24, 2020, one-third on October 24, 2021, and will be fully vested on October 24, 2022. Read SEC document |
| May 02, 2019 Filed May 3, 2019 19:47 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantOptions to purchase common stock · Derivative | 35,000 | $0.00 Strike: $14.35 | $0.00 |
DisclosureSEC source: 0001144204-19-023715 · tv520657_form4.xml · derivative · entry 1 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2029-05-02 F1 · derivative.exercise_date: 1/12 of these options vested and became exercisable in equal monthly installments on the 2nd of each month for the next twelve (12) months beginning on 05/02/2019. Read SEC document |
| March 15, 2019 Filed Mar 18, 2019 16:01 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionOptions to purchase common stock · Derivative | 30,000 | $0.00 Strike: $3.07 | $0.00 |
DisclosureSEC source: 0001144204-19-014613 · tv516448_4.xml · derivative · entry 3 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,300 Underlying: Common Stock · 30,000 shares Expires 2025-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/48 of the 113,300 options originally granted vest on the 19th of each month for forty-eight months beginning on August 19, 2015. Read SEC document |
| March 15, 2019 Filed Mar 18, 2019 16:01 UTC | Cryoport, Inc. CYRX · Entity 5125 | SaleCommon Stock | 30,000 | $11.84 | $355,161.00 |
DisclosureSEC source: 0001144204-19-014613 · tv516448_4.xml · nonDerivative · entry 2 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| March 15, 2019 Filed Mar 18, 2019 16:01 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionCommon Stock | 30,000 | $3.07 | $92,100.00 |
DisclosureSEC source: 0001144204-19-014613 · tv516448_4.xml · nonDerivative · entry 1 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2018 Filed Nov 16, 2018 14:35 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionOptions to purchase common stock · Derivative | 10,200 | $0.00 Strike: $3.07 | $0.00 |
DisclosureSEC source: 0001144204-18-060465 · tv507471_4.xml · derivative · entry 6 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,300 Underlying: Common Stock · 10,200 shares Expires 2025-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/48 of the 113,300 options originally granted vest on the 19th of each month for forty-eight months beginning on August 19, 2015. Read SEC document |
| November 15, 2018 Filed Nov 16, 2018 14:35 UTC | Cryoport, Inc. CYRX · Entity 5125 | SaleCommon Stock | 10,200 | $10.00 | $102,000.00 |
DisclosureSEC source: 0001144204-18-060465 · tv507471_4.xml · nonDerivative · entry 4 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| November 15, 2018 Filed Nov 16, 2018 14:35 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionCommon Stock | 10,200 | $3.07 | $31,314.00 |
DisclosureSEC source: 0001144204-18-060465 · tv507471_4.xml · nonDerivative · entry 3 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 14, 2018 Filed Nov 16, 2018 14:35 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionOptions to purchase common stock · Derivative | 19,800 | $0.00 Strike: $3.07 | $0.00 |
DisclosureSEC source: 0001144204-18-060465 · tv507471_4.xml · derivative · entry 5 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,500 Underlying: Common Stock · 19,800 shares Expires 2025-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/48 of the 113,300 options originally granted vest on the 19th of each month for forty-eight months beginning on August 19, 2015. Read SEC document |
| November 14, 2018 Filed Nov 16, 2018 14:35 UTC | Cryoport, Inc. CYRX · Entity 5125 | SaleCommon Stock | 19,800 | $10.09 | $199,722.60 |
DisclosureSEC source: 0001144204-18-060465 · tv507471_4.xml · nonDerivative · entry 2 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.0059 to $10.184, inclusive. The reporting person undertakes to provide to Cryoport, Inc., any security holder of Cryoport, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| November 14, 2018 Filed Nov 16, 2018 14:35 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionCommon Stock | 19,800 | $3.07 | $60,786.00 |
DisclosureSEC source: 0001144204-18-060465 · tv507471_4.xml · nonDerivative · entry 1 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 05, 2018 Filed Nov 7, 2018 17:00 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | GrantOption · Derivative | 25,000 | $0.00 Strike: $0.54 | $0.00 |
DisclosureSEC source: 0001493152-18-015361 · form4.xml · derivative · entry 1 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-11-05 F1 · shares: This award relates to the annual long term incentive grant awarded by the Compensation Committee following the completion of our 2018 Fiscal Year and is subject to the terms of our 2015 Incentive Plan. The award vests one-third on November 5, 2019, one-third on November 5, 2020, and will be fully vested on November 5, 2021. Read SEC document |
| September 13, 2018 Filed Dec 21, 2018 19:13 UTC | Cuentas Inc. CUEN · Entity 8361 | GrantOption to purchase Common Stock* · Derivative | 30,000 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0001213900-18-017771 · ownership.xml · derivative · entry 1 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock, par value $0.001 per share · 30,000 shares Expires 2023-09-13 F1 · shares: The 30,000 options to purchase shares of the Issuer's common stock were issued in connection with a grant under the Issuer's 2018 Equity Stock Incentive Plan. F2 · derivative.exercise_date: 10,000 options are exercisable at 9/13/2018; 10,000 options are exercisable at 9/13/2019; 10,000 options are exercisable at 9/13/2020. Read SEC document |
| September 06, 2018 Filed Sep 7, 2018 17:34 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionOption to Purchase Common Stock · Derivative | 10,000 | $0.00 Strike: $3.07 | $0.00 |
DisclosureSEC source: 0001144204-18-048613 · tv502589_4.xml · derivative · entry 3 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,300 Underlying: Common Stock · 10,000 shares Expires 2025-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/48 of the 113,300 options originally granted vest on the 19th of each month for forty-eight months beginning on August 19, 2015. Read SEC document |
| September 06, 2018 Filed Sep 7, 2018 17:34 UTC | Cryoport, Inc. CYRX · Entity 5125 | SaleCOMMON STOCK | 10,000 | $14.00 | $140,024.00 |
DisclosureSEC source: 0001144204-18-048613 · tv502589_4.xml · nonDerivative · entry 2 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| September 06, 2018 Filed Sep 7, 2018 17:34 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionCOMMON STOCK | 10,000 | $3.07 | $30,700.00 |
DisclosureSEC source: 0001144204-18-048613 · tv502589_4.xml · nonDerivative · entry 1 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 15, 2018 Filed Aug 17, 2018 06:06 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionOption to Purchase Common Stock · Derivative | 20,000 | $0.00 Strike: $3.07 | $0.00 |
DisclosureSEC source: 0001144204-18-045223 · tv501229_4.xml · derivative · entry 3 BERMAN RICHARD J · CIK 0001111620 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,300 Underlying: Common Stock · 20,000 shares Expires 2025-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/48 of the 113,300 options originally granted vest on the 19th of each month for forty-eight months beginning on August 19, 2015. Read SEC document |
| August 15, 2018 Filed Aug 17, 2018 06:06 UTC | Cryoport, Inc. CYRX · Entity 5125 | SaleCOMMON STOCK | 20,000 | $12.81 | $256,238.00 |
DisclosureSEC source: 0001144204-18-045223 · tv501229_4.xml · nonDerivative · entry 2 BERMAN RICHARD J · CIK 0001111620 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| August 15, 2018 Filed Aug 17, 2018 06:06 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionCOMMON STOCK | 20,000 | $3.07 | $61,400.00 |
DisclosureSEC source: 0001144204-18-045223 · tv501229_4.xml · nonDerivative · entry 1 BERMAN RICHARD J · CIK 0001111620 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 02, 2018 Filed Aug 3, 2018 21:42 UTC | Ontrak, Inc. CATS · Entity 78207 | GrantStock Option to purchase Common Stock · Derivative | 30,624 | Not disclosed Strike: $7.50 | Not disclosed |
DisclosureSEC source: 0001437749-18-014477 · rdgdoc.xml · derivative · entry 1 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,624 Underlying: Common Stock · 30,624 shares Expires 2028-08-02 F1 · kind: These options were granted to Mr. Berman for his services as a member of the Company's Board of Directors. F1 · price: These options were granted to Mr. Berman for his services as a member of the Company's Board of Directors. F2 · derivative.exercise_date: These options have a three-year vesting period out of which 8,814 shares vested on August 2, 2018, the grant date, and 21,810 shares shall vest at the end of each calendar quarter for the 2018 and 2019 calendar years beginning January 1, 2018, such that all shares shall vest on December 31, 2019. Quarterly vesting of the option will be subject to Mr. Berman attending board meetings, unless such absence is excused by the Chairman of the board. All unvested options will immediately vest in the event of termination without cause. Read SEC document |
| June 26, 2018 Filed Jun 27, 2018 17:15 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | GrantCommon stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-18-009308 · ownership.xml · nonDerivative · entry 1 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,669 F1 · shares: Represents restricted stock units awarded as compensation for services on the Executive Committee of the Board of Directors. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.